The US Food and Drug Administration granted regular approval to a maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The US Food and Drug Administration has approved a new option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
In response to several reported deaths, the FDA has issued a warning to alert health care providers of potential mortality risk related to intragastric balloon systems.
After its efficacy was demonstrated in a clinical trial, the US Food and Drug Administration approved a new treatment options for adult patients with 2 types of poor-prognosis acute myeloid leukemia.
After results from a recent trial demonstrated its efficacy, the FDA expanded the indication of a cancer drug to include adult patients with chronic graft versus host disease who do not respond to other...
The FDA granted accelerated approval to a new treatment for adolescent and adult patients with mismatch repair deficient and microsatellite instability metastatic colorectal cancer.
